Lifecore Biomedical Announces $6.28/Share Buyout Plus CVRs by Webster

What Happened

• Lifecore Biomedical, Inc. (filed 8-K on Sept. 28, 2026) entered into a definitive Agreement and Plan of Merger dated Sept. 27, 2026 with Lifecore Inc. (Parent) and Hazel Merger Sub, affiliates of Webster Equity Partners. Under the deal, each outstanding common share (excluding certain excluded shares) will be converted into $6.28 in cash plus one contingent value right (CVR). The Lifecore Board and its Transaction Committee unanimously recommended the merger. The Company will be delisted from Nasdaq and deregistered if the merger closes.

Key Details

• Purchase consideration: $6.28 cash per share + one CVR per share (CVRs are non-tradeable contractual rights, not equity).
• CVR payout structure: up to $30M for a 2028 milestone, $45M for 2029, and $85M for 2030 (total potential milestone pool $160M), with specified partial payouts, catch-up mechanics and up to $10M adjustments for certain litigation.
• Treatment of equity awards: options vest immediately; in-the-money options converted to cash equal to (Base Consideration − exercise price) × shares plus one CVR per share; options priced ≥ $6.28 are cancelled without payment; RSUs/PSUs convert into the merger consideration with specific PSU payout mechanics.
• Closing conditions and protections: stockholder approval, HSR clearance and other regulatory/consent conditions. Deal requires certain Alcon-related contracts to remain in effect. Termination fees: Go-shop $7,468,287; Company termination $9,957,716; Reverse termination $16,181,288.
• Financing: Parent has $400M equity commitments from Webster affiliates and debt commitments totaling $150M ($115M term loans + $30M revolver from lenders and $35M term loan from Alcon); financing is available but not a closing condition. Voting & Support agreements were signed with major stockholder groups affiliated with two directors.

Why It Matters

• This is a definitive sale of Lifecore to a Webster-affiliated buyer at a fixed cash price plus contingent upside through CVRs tied to multi-year revenue/EBITDA milestones. Retail investors should note the immediate cash component ($6.28/share), the uncertain value of the CVRs (payments depend on future performance and are non-transferable), and that company stock will be delisted if the deal closes. The agreement also accelerates and converts equity awards in specific ways that affect employees and option holders. Key closing hurdles include shareholder approval and antitrust/regulatory clearances; specified commercial agreements with Alcon must continue to be in effect for the deal to close.